RxDoctor Payments Data

Leonel Apodaca, MD

Internal Medicine · Coalinga, CANPI 1699883157

Payments from drug & device makers

$1,766in general payments, 2019–2025

Across 87 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$916
  • Novo Nordisk$232
  • AstraZeneca$172
  • Merck$155
  • Mylan Specialty L.p.$74
  • Xeris Pharmaceuticals, Inc.$67
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$1,766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,766 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$17,894
Medicare patients
157
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate121$131,646
EliquisApixaban125$117,830
JardianceEmpagliflozin87$89,317
OzempicSemaglutide69$59,338
TradjentaLinagliptin44$48,010
JanumetSitagliptin Phos/Metformin Hcl24$33,614
EntrestoSacubitril/Valsartan22$30,751
KeppraLevetiracetam11$24,751
XareltoRivaroxaban16$22,775
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$16,472
FarxigaDapagliflozin Propanediol11$15,371
TrulicityDulaglutide11$11,937
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$8,038
InvokanaCanagliflozin12$7,067
Breo ElliptaFluticasone/Vilanterol20$6,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$155$165,260145 claims
Boehringer IngelheimJardiance, Tradjenta$916$137,328131 claims
Novo NordiskOzempic$232$59,33869 claims
AstraZenecaFarxiga$172$15,37111 claims
Lilly USA, LLCTrulicity$35$11,93711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Coalinga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →